What’s new, what’s next and where to find us. This is your hub for our CRO lab announcements, insights and events—because in bioanalysis, momentum matters.
Our CEO, Shane Needham, PhD, was recently featured in The Analytical Scientist discussing the impact of GLP-1 receptor agonists and emerging peptide therapeutics.
Veloxity Labs has acquired the SCIEX ZenoTOF 8600 system, becoming the first bioanalytical CRO to bring this accurate-mass system online. The 8600 adds HRAM selectivity/sensitivity and expanded mass range for intact peptides/proteins—speeding method cycles for GLP-1 RAs and broader peptide programs while complementing our triple-quads. Delivery is expected this year; install/qualification begins January 2026.
Read the full release.
We’ve partnered with Carolina Martinez — a record-setting sprinter, Bradley University standout and cancer survivor — in a powerful new NIL collaboration.
We’re proud to support Silo Pharma in advancing SPC-15, a novel intranasal therapy for PTSD. We're providing GLP bioanalysis for their IND-enabling safety study.
Veloxity Labs is proud to announce a partnership with Aplos Analytics. This collaboration brings enhancements to PK/TK analysis for lightning-fast results in minutes.
Veloxity will be attending and sponsoring lunch at the PBSS Vendor Scientific Highlights Symposium to connect with peers working on large-molecule programs.
Veloxity’s President and CEO, Shane Needham, will be joining a panel discussion at Lights, Data, Action: The Future of Bioscience & Healthcare, on April 28th.
Veloxity will be attending the 2026 State of Possible Conference to engage with companies navigating growth, operational scale-up, and development execution.
